<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01008657</url>
  </required_header>
  <id_info>
    <org_study_id>P071213</org_study_id>
    <nct_id>NCT01008657</nct_id>
  </id_info>
  <brief_title>Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique</brief_title>
  <acronym>ARMCENVIN</acronym>
  <official_title>Multipolar Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma Using Classical Intranodular Technique Versus Extra Nodular Technique So-called &quot;No Touch&quot; Technique: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the trial is to demonstrate that at least a 40% drop of recurrence
      rate can be achieve in hepatocellular carcinoma patients treated with no touch multipolar
      radiofrequency ablation technique compared to those treated with usual intranodular
      multipolar technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      206 patients with hepatocellular carcinoma(s) including up to three nodules measuring up to
      four cm in diameter, will be randomized in two therapeutic legs: multipolar no touch
      radiofrequency versus multipolar intra nodular radiofrequency. Patients previously treated
      for hepatocellular carcinoma will not be enrolled in the study. Diagnostic of hepatocellular
      carcinoma will be based on American Society of Liver Diseases guide line. Early response to
      the treatment will be assessed one month after the radiofrequency ablation procedures (up to
      three in case of incomplete necrosis) with dynamic contrast medium enhanced CT or MRI liver
      examinations. For the follow up dynamic contrast medium enhanced CT or MRI liver examinations
      will be performed every three months.

      The trial will last for 73 months including 45 months for the recruitment of patients. The
      main criteria of judgement will be the 2-years recurrence rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2010</start_date>
  <completion_date type="Actual">October 6, 2016</completion_date>
  <primary_completion_date type="Actual">October 6, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 years global (local+distant) recurrence rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2 years local recurrence rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 years distant recurrence rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary treatment effectiveness (assessed 1 month after completion of treatment course which can include up to 3 radiofrequency ablation (RFA) procedures performed monthly)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Hepatocellular Carcinomas</condition>
  <arm_group>
    <arm_group_label>extranodular &quot;no touch&quot; multipolar RFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intranodular multipolar RFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>Percutaneous multipolar radiofrequency ablation.</description>
    <arm_group_label>extranodular &quot;no touch&quot; multipolar RFA</arm_group_label>
    <arm_group_label>intranodular multipolar RFA</arm_group_label>
    <other_name>radiofrequency extranodular or intanodular ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt; 18 years old, holder of up to 3 nodules less than 4 cm in diameter

          -  Diagnosis of hepatocellular carcinoma according to American Society of Liver Study non
             invasive criteria or based on histological proof

          -  Non invasive diagnosis of cirrhosis according to French Haute Authority of illness
             guideline or based on histological proof

          -  No previous treatment for hepatocellular carcinoma

          -  Multidisciplinary decision of treatment by radiofrequency ablation

        Exclusion Criteria:

          -  Adult patient under guardianship or trusteeship, homeless

          -  Patient with potentially short term life-threatening serious co-infection (apart from
             viral B or C, or VIH co-infection)

          -  Pregnant or breastfeeding woman

          -  Patient for whom regular follow-up is impossible whatever the cause

          -  Contra indication to general anaesthesia

          -  Technical impossibility to perform the procedure under ultrasound guidance

          -  Boundary of the tumor located at less than 1 cm distance from colonic wall or main
             biliary tract (main right or left bill ducts and common bill duct)

          -  Tumor invisible with ultrasound

          -  Lack of safe percutaneous course which can be planned

          -  Tumor in which more than four biopsies pass were previously performed (cumulated
             during one or several previous biopsies sessions)

          -  Contra indication to perform CT or MRI with contrast medium (GADOLINITE or iodinate)
             intravenous injection

          -  Child-Pugh B or C cirrhosis (apart from the transitory liver failures in the setting
             of acute hepatitis related to alcohol abuse)

          -  Total detachment of the anterior face of the liver from internal abdominal wall due to
             abundant ascites.

          -  Prothrombin activity &lt; 50 %

          -  Platelet count &lt;40 .10 3/ml

          -  Platelet dysfunction or congenital impaired blood coagulating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Seror, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiology Department, CHU-Jean Verdier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiology Department</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8.</citation>
    <PMID>16495695</PMID>
  </reference>
  <reference>
    <citation>Kotoh K, Enjoji M, Arimura E, Morizono S, Kohjima M, Sakai H, Nakamuta M. Scattered and rapid intrahepatic recurrences after radio frequency ablation for hepatocellular carcinoma. World J Gastroenterol. 2005 Nov 21;11(43):6828-32.</citation>
    <PMID>16425391</PMID>
  </reference>
  <reference>
    <citation>Seror O, N'Kontchou G, Tin-Tin-Htar M, Barrucand C, Ganne N, Coderc E, Trinchet JC, Sellier N, Beaugrand M. Radiofrequency ablation with internally cooled versus perfused electrodes for the treatment of small hepatocellular carcinoma in patients with cirrhosis. J Vasc Interv Radiol. 2008 May;19(5):718-24. doi: 10.1016/j.jvir.2008.01.007. Epub 2008 Mar 17.</citation>
    <PMID>18440461</PMID>
  </reference>
  <reference>
    <citation>Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, Dela Torre A, Cho KC, Contractor D, Korogodsky M. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2003 Nov;197(5):759-64.</citation>
    <PMID>14585410</PMID>
  </reference>
  <reference>
    <citation>Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchianò A, Spreafico C, Camerini T, Mariani L, Miceli R, Andreola S. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004 Nov;240(5):900-9.</citation>
    <PMID>15492574</PMID>
  </reference>
  <reference>
    <citation>Kotoh K, Morizono S, Kohjima M, Enjoji M, Sakai H, Nakamuta M. Evaluation of liver parenchymal pressure and portal endothelium damage during radio frequency ablation in an in vivo porcine model. Liver Int. 2005 Dec;25(6):1217-23.</citation>
    <PMID>16343075</PMID>
  </reference>
  <reference>
    <citation>Kotoh K, Nakamuta M, Morizono S, Kohjima M, Arimura E, Fukushima M, Enjoji M, Sakai H, Nawata H. A multi-step, incremental expansion method for radio frequency ablation: optimization of the procedure to prevent increases in intra-tumor pressure and to reduce the ablation time. Liver Int. 2005 Jun;25(3):542-7.</citation>
    <PMID>15910491</PMID>
  </reference>
  <reference>
    <citation>Nakamuta M, Kohjima M, Morizono S, Yoshimoto T, Miyagi Y, Sakai H, Enjoji M, Kotoh K. Comparison of tissue pressure and ablation time between the LeVeen and cool-tip needle methods. Comp Hepatol. 2006 Dec 21;5:10.</citation>
    <PMID>17181870</PMID>
  </reference>
  <reference>
    <citation>Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002 Nov 1;95(9):1931-7.</citation>
    <PMID>12404287</PMID>
  </reference>
  <reference>
    <citation>Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005 Sep;11(9):1086-92.</citation>
    <PMID>16123959</PMID>
  </reference>
  <reference>
    <citation>Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007 Jan;245(1):36-43.</citation>
    <PMID>17197963</PMID>
  </reference>
  <reference>
    <citation>Seror O, N'Kontchou G, Ibraheem M, Ajavon Y, Barrucand C, Ganne N, Coderc E, Trinchet JC, Beaugrand M, Sellier N. Large (&gt;or=5.0-cm) HCCs: multipolar RF ablation with three internally cooled bipolar electrodes--initial experience in 26 patients. Radiology. 2008 Jul;248(1):288-96. doi: 10.1148/radiol.2481071101. Epub 2008 May 15.</citation>
    <PMID>18483229</PMID>
  </reference>
  <reference>
    <citation>Wong IH, Yeo W, Leung T, Lau WY, Johnson PJ. Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: a quantitative evaluation. Cancer Lett. 2001 Jun 26;167(2):183-91.</citation>
    <PMID>11369140</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2009</study_first_submitted>
  <study_first_submitted_qc>November 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2009</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiofrequency-Extranodular-Multipolar ablation</keyword>
  <keyword>Recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

